Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2025-03-25 Transaction in Own Shar…
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding a decision to enter into a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 체결 결정). This is a specific corporate action involving the company buying back its own shares through a trust, which falls under the 'Transaction in Own Shares' category.
2025-03-25 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, revenue, profit/loss) for the current and previous fiscal years, and details regarding the external auditor. While it contains financial data, it is a structured regulatory disclosure announcement rather than the full annual report document itself. Therefore, it fits the definition of a regulatory filing announcement. FY 2024
2025-03-21 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for LigaChem Biosciences for the fiscal year ending December 31, 2024. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. It is not an Annual Report (10-K) as it lacks the broader management discussion and analysis (MD&A) and business overview typically found in a full 10-K, focusing specifically on the audit and financial statements. FY 2024
2025-03-21 Korean
투자판단관련주요경영사항 ('LCB97'관련 마일스톤 기술료 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from LigaChem Biosciences regarding the receipt of a milestone payment for a previously disclosed technology transfer agreement ('LCB97'). It is a specific disclosure of a material business event (major management matter) filed with the KRX. Since it does not fit into specific categories like M&A, dividends, or share transactions, and is a standard regulatory disclosure of a business event, it is classified as a Regulatory Filing (RNS).
2025-03-14 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Ligachem Biosciences. It contains the meeting agenda, details on board activities, financial statements, and governance information. While it includes financial data, it is primarily a formal notice to shareholders regarding the upcoming AGM, which falls under the category of AGM Information (AGM-R).
2025-03-14 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for LigaChem Biosciences. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and stock option grants). This type of document is a standard proxy solicitation material provided to shareholders to inform them of upcoming meeting details and agenda items, which falls under the Proxy Solicitation & Information Statement category.
2025-03-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.